Credit Suisse vs Nomura
GLDI and NMR side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GLDI | NMR |
|---|---|---|
| Size and price | ||
| Share price | $127.16 | $9.23 |
| Change, 1 year | −25.4% | 32.0% |
| Change, 5 years | −24.0% | 119% |
| Beta (5Y) | 0.16 | 0.96 |
| StockData Score | ||
| Total score | – | 5 |
| Valuation score | – | 0 |
| Growth score | – | 2 |
| Performance score | – | 2 |
| Health score | – | 1 |
| Dividend score | – | 0 |
| Growth | ||
| Revenue growth (TTM) | – | 0.46% |
| Revenue growth, 5Y average | – | 24.1% |
| Net income growth (TTM) | – | 6.3% |
| EPS growth (TTM) | – | 7.2% |
| EPS growth, 5Y average | – | 19.6% |
| Profitability | ||
| Net margin | – | 7.6% |
| FCF margin | – | −25.2% |
| Return on equity | – | 10.1% |
| Financial health | ||
| Debt / equity | – | 0.47 |
| Net debt / EBITDA | – | −0.80 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Payout ratio | – | 49.6% |
| Ownership | ||
| Held by institutions | 0.01% | 3.0% |
| Held by insiders | 0.00% | 0.12% |
| Insider net buying, 12 months | – | $3.9K |
Go deeper
- GLDI stock overview
- GLDI income statement
- GLDI valuation and score
- NMR stock overview
- NMR income statement
- NMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.